U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06951217) titled 'An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)' on April 08.
Brief Summary: This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.
All participants will receive 100 mg inhaled pirfenidone inhalation solution (AP01) taken twice daily using the eFlow Nebulizer System for until such a time that the drug is approved, the pa...